. The determination of inflammatory activity is crucial for patients with IBD for the diagnosis, monitoring and step up of therapy. Clinical indices are widely used but are hampered by the subjective nature of symptom reporting and have been shown to be poorly correlated with mucosal activity 6 . Colonoscopy is the accepted gold standard for investigation of the colon but is invasive and associated with risks 7 . Whilst there is emerging evidence of activation of the mucosal innate defence system toward a pro-inflammatory response in IBS patients , the absence of endoscopic and histological inflammation remains an accepted approach to the diagnosis of IBS by the bedside 8 .
Lactoferrin (LF) is an iron binding glycoprotein secreted by most mucosal membranes and a major component of secondary granules of polymorphonuclear neutrophils, a component of the inflammatory response 9, 10 . Elevated LF has been used as a marker of active IBD [11] [12] [13] [14] [15] [16] and for monitoring patients for response to treatment 17 . Some studies report a high sensitivity of LF for active IBD in comparison to IBS. However the use of LF for the distinction of inactive IBD and IBS is less clear 13, 14, 18, 19 . Table 1 tabulates the comparative 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   5 studies of patients with IBD and IBS using LF 11, [13] [14] [15] [16] 19 .
The aim of this study was to investigate the clinical utility of LF as a marker of GI inflammation in patients with active and inactive IBD compared to patients with diarrhoea predominant IBS and healthy controls.
Methods

Patients
Consecutive patients were recruited from the outpatient clinic. Patients with inflammatory bowel disease were questioned about their general well being, the frequency of bowel habit, the presence/ absence of abdominal pain or blood in the stool. Patients with established IBD were given a Harvey Bradshaw Index (HBI) for Crohn's disease and a (previously validated) modified HBI for Ulcerative colitis (Appendix 1) 15 . Patients with HBI of ≥ 4
were considered to have active disease. All patients who had diarrhoea with the presence of abdominal discomfort and who fulfilled the Rome II criteria for diarrhoea predominant IBS were also recruited. 4, 5 All patients were investigated and treated according to the British Society of Gastroenterology guidelines 4 . Colonoscopy was requested based on clinical need. Healthy controls were recruited after exclusion of disease with a questionnaire. All participants were requested to return a stool sample in a container provided. Ethical approval was obtained from the North Sheffield Ethics Committee.
Stool analysis
Analysis was performed blind to the clinical details of the patient. Stool samples were frozen at -20 degrees Celsius (C) immediately on receipt. Quantitative ELISA (IBD SCAN) 
Statistical analysis
The data was analyzed using SPSS version 15. Non parametric tests (Mann Whitney U test)
were used to compare lactoferrin concentrations between groups as the data was not normally distributed. Kendal tau correlations were performed to assess the relationship between lactoferrin concentration and disease activity (HBI). Assistance was also sought from the University of Sheffield statistics department.
Results
Four hundred and sixty five patients were recruited between November 2006 and October
2008
. The mean age in the IBS, UC and Crohn's group was 42 years, 58 years and 56 years respectively. The median LF levels were significantly higher in patients with IBD compared to patients with IBS (P<0.001) and healthy controls (p<0.001). Table 2 tabulates the mean and median LF values for each group whilst Figure 1 shows the distribution of LF values in all patients.
Among patients with IBD, there was a trend towards higher LF values in patients with UC compared to patients with CD (p=0.051). As for stratification based on severity of symptoms/ disease activity, the median LF (ug/g) levels were significantly higher in patients with active disease (HBI ≥4) compared to patients with inactive disease for both UC and CD (p<0.001 and p=0.002 respectively). Analysis of LF levels in IBD patients based on disease activity is tabulated in Table 3 . The sensitivity and specificity of LF for active IBD versus IBS patients was 67% and 96% respectively with positive and negative predictive values of 92% and 80% respectively. Similar calculations for active UC and CD patients are tabulated in Table 4 . ROC curves were calculated to illustrate the trade off between the sensitivity and specificity for each group as shown in Figure 2a -2c.
Discussion
This study, the largest to date on the use of LF (n=465), has shown that LF has a high sensitivity and specificity for the discrimination of patients with active IBD against patients with IBS and healthy controls. In addition, LF levels were significantly higher in patients with inactive IBD compared to patients with IBS, making it a valuable investigative tool in patients where the differentiation is difficult, based on clinical history alone. Whilst the poor correlation between symptom reporting and disease activity in IBD has been demonstrated before 6 , previous LF studies making similar comparisons have shown conflicting results with some studies failing to show a difference between inactive IBD and IBS 13, 18, 19 . 11, 20 .In a recent study LF predicted post operative recurrence in Crohn's disease with greater accuracy than C-reactive protein, platelet count or endoscopic appearance 17 .
In our study, the median LF levels in IBD patients were comparatively lower compared to other studies in the published literature 14, 15 . This could be explained by the larger number of patients with inactive disease. The inclusion of patients into this study was based on recruitment from routine outpatient clinics from a single centre as opposed to specially selected patients with severe symptoms.
A perceived limitation of our study is the lack of correlation with endoscopic and histological grading. In our study, colonoscopy was only performed based on clinical need and represented less than 30% of the population group. In addition, the endoscopies which were performed as routine care were done by a number of endoscopists. Similarly biopsies from these patients were also analysed by a number of histopatholgists making meaningful comparisons difficult. Previous investigators have demonstrated that LF has a good correlation with endoscopic grading 14 .
LF is an inexpensive and non invasive test that can provide the clinician with a marker to differentiate between IBD (particularly active disease) and IBS and stratify patients who 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).
16
The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).
5
Test results 17 Time-interval between the index tests and the reference standard, and any treatment administered in between.
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